Next generation sequencing (NGS) also known as high-throughput sequencing enables scientists to sequence and assemble billions of short DNA reads. The advent of next generation sequencing technologies has brought significant changes in the sequencing process by providing high throughput, speed, flexibility and reduced sequencing cost over thousand folds. NGS has ability to generate hundreds of gigabases of nucleotide sequence data in a single sequencing run. The technology is emerging at a rapid rate due to its growing adoption in clinical applications as it allows scanning of whole genomes or targeted genomes in less span of time. In addition, reduction in cost of sequencing has also expanded the usage of next generation sequencing in variety of clinical applications. The technique has imparted its usage in various clinical applications such as cancer, inherited genetic disorders, HLA typing and identification of infectious diseases. For instance, NGS has been used for tracing hospital acquired infections and tuberculosis outbreaks.
The market for next generation sequencing can be segmented based on technology, application, end-users and geography. The application section can be categorized into drug discovery, personalized medicines, biomarker discovery, diagnostics and others (agriculture, animal, marine and other studies). The technology section of the market could be subdivided into sequencing by synthesis, ion semiconductor sequencing, pyrosequencing, sequencing by ligation and single molecule real time sequencing. The next generation sequencing market can also be analyzed based on the end user segment including hospitals and clinics, research institutions and pharmaceutical and biotechnology companies. It is witnessed that more than 65% of the next generation sequencing revenue is generated from academic institutions, biopharmaceutical companies and government research institutes. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Latin America (LATAM), and Middle East and Africa (MENA). Of all the geographies, North America accounted for the largest market share in 2014 followed by Europe. However, during the forecast period Asia-Pacific region is anticipated to record highest growth owing to market saturation in developed regions. Furthermore, technological innovation, increasing drug discovery initiatives by healthcare companies, increasing adoption of innovative models and huge capital investment by pharmaceutical and biotechnology companies are some of the key factors expected to drive the growth of next generation sequencing market in Asia.
Currently, the next generation sequencing market is consolidated with very few market players due to involvement of extremely complicated technologies and the low target audience for the systems. The expensive next-generation sequencing systems may exceed a cost of millions of dollars for installation, maintenance, reagents and output analysis. Most respondents have suggested sequencing as a service business rather than an investment for in-house research. Introduction of bench-top sequencers enabling ease of use to researchers is also expected to push the market growth further. Outsourcing sequencing is expected to remain a major contributor to the revenue generation in the coming years. Response gathered from research facilities suggest that purchase of these sequencing platforms may demonstrate actual growth post reduction in the sequencing costs below USD 1000 as suggested by several manufacturers. True potential of this technology lies in the personalized medicine and sequencing genomes of individuals. Furthermore, increasing initiatives by government bodies for genomics research would also boost the adoption of high-throughput sequencing platform.
Some of the major players operating in the global NGS market are Agilent Technologies, Life Sciences Corporation (Roche Holding Ag), Genomatix Software Gmbh, Illumina, Inc., Gatc Biotech Ag, Dnastar, Inc., Life Technologies Corporation, Oxford Nanopore Technologies, Ltd., Perkin Elmer, Inc., Qiagen N.V., Partek Incorporated, Macrogen, Inc., Knome, Inc., and Genomatix Software Gmbh.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.